Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462942 | 0.83 | STS (0.48) | GPR119GRM5F13A1TGM2TGM1 | |
| SCHEMBL23119314 | 0.82 | GRM5 (0.50) | GPR119GRM5F13A1TGM2TGM1 | |
| SCHEMBL16113475 | 0.80 | GPR119 (0.53) | GPR119GRM5CYP1A2 | |
| SCHEMBL6154292 | 0.79 | GPR119 (0.52) | GPR119GRM5 | |
| SCHEMBL6393733 | 0.78 | GRM5 (0.51) | GPR119GRM5CYP1A2 | |
| SCHEMBL20169983 | 0.77 | ESR2 (0.49) | GPR119 | |
| SCHEMBL29574544 | 0.77 | ESR2 (0.49) | GPR119 | |
| SCHEMBL18280115 | 0.77 | GRM5 (0.42) | GPR119GRM5F13A1TGM2TGM1 | |
| SCHEMBL23783134 | 0.76 | GPR119 (0.39) | GPR119GRM5F13A1TGM2TGM1 | |
| SCHEMBL460272 | 0.76 | GRM5 (0.47) | GPR119GRM5F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | BASILEA PHARM INT AG (CH) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142810-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | NDUFAB1, FH, MT-ND1 | GPR119 855/4885GRM5 4580/4885CYP1A2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.